JP2023504172A5 - - Google Patents
Info
- Publication number
- JP2023504172A5 JP2023504172A5 JP2022532773A JP2022532773A JP2023504172A5 JP 2023504172 A5 JP2023504172 A5 JP 2023504172A5 JP 2022532773 A JP2022532773 A JP 2022532773A JP 2022532773 A JP2022532773 A JP 2022532773A JP 2023504172 A5 JP2023504172 A5 JP 2023504172A5
- Authority
- JP
- Japan
- Prior art keywords
- mhc class
- chain
- molecule
- mhc
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025132396A JP2025159063A (ja) | 2019-12-02 | 2025-08-07 | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942344P | 2019-12-02 | 2019-12-02 | |
| US62/942,344 | 2019-12-02 | ||
| PCT/US2020/062801 WO2021113297A1 (en) | 2019-12-02 | 2020-12-02 | Peptide-mhc ii protein constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025132396A Division JP2025159063A (ja) | 2019-12-02 | 2025-08-07 | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504172A JP2023504172A (ja) | 2023-02-01 |
| JP2023504172A5 true JP2023504172A5 (enExample) | 2023-11-29 |
| JP7726881B2 JP7726881B2 (ja) | 2025-08-20 |
Family
ID=74046157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532773A Active JP7726881B2 (ja) | 2019-12-02 | 2020-12-02 | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
| JP2025132396A Pending JP2025159063A (ja) | 2019-12-02 | 2025-08-07 | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025132396A Pending JP2025159063A (ja) | 2019-12-02 | 2025-08-07 | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220409732A1 (enExample) |
| EP (1) | EP4069722A1 (enExample) |
| JP (2) | JP7726881B2 (enExample) |
| KR (1) | KR20220110233A (enExample) |
| CN (1) | CN114901678A (enExample) |
| AU (1) | AU2020395122A1 (enExample) |
| CA (1) | CA3163549A1 (enExample) |
| IL (1) | IL293330A (enExample) |
| WO (1) | WO2021113297A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| CN118813436A (zh) * | 2023-07-24 | 2024-10-22 | 佳吾益(北京)科技有限公司 | 展示单mhc等位基因功能蛋白的工程化细胞 |
| WO2025064770A2 (en) * | 2023-09-20 | 2025-03-27 | La Jolla Institute of Immunology | Alphavirus t cell epitopes, megapools and uses thereof |
| EP4780844A1 (en) | 2023-09-22 | 2026-07-29 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibody molecules binding to a peptide-mhc interface |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7795494B2 (en) | 2001-03-22 | 2010-09-14 | Abbott Laboratories | Transgenic mice expressing antibodies specific for genes of interest and uses thereof |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| KR101703299B1 (ko) | 2007-06-01 | 2017-02-06 | 오픈 모노클로날 테크놀로지, 인코포레이티드 | 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물 |
| EP3456191A1 (en) | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
| PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
| WO2010037397A1 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cmv immune monitoring |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| GB201002730D0 (en) * | 2010-02-18 | 2010-04-07 | Uni I Oslo | Product |
| PL3248462T3 (pl) | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| WO2011147894A1 (en) * | 2010-05-25 | 2011-12-01 | Forschungsverbund Berlin E.V. | Chimeric mhc class ii proteinpeptide |
| MY195217A (en) | 2010-06-22 | 2023-01-11 | Regeneron Pharma | MICE Expressing An Immunoglobulin Hybrid Light Chain |
| CN103025884B (zh) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
| JP2012120488A (ja) | 2010-12-09 | 2012-06-28 | Univ Of Tokyo | 新規安定化組換えｍｈｃタンパク質 |
| CN105861548B (zh) | 2011-02-25 | 2020-01-10 | 瑞泽恩制药公司 | Adam6小鼠 |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| EP4074833A1 (en) | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| RS61455B1 (sr) | 2011-10-28 | 2021-03-31 | Regeneron Pharma | Genetski modifikovani miševi t ćelijskog receptora |
| RU2014132426A (ru) | 2012-01-06 | 2016-02-27 | Орегон Хэлт Энд Сайенс Юниверсити | Частичные конструкты мнс и способы их применения |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2014093908A2 (en) | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
| US9475559B2 (en) | 2013-07-03 | 2016-10-25 | Hobie Cat Company | Foot operated propulsion system for watercraft |
| US9410301B2 (en) | 2014-12-09 | 2016-08-09 | Theophile Bourgeois | Patch system and method for oil boom |
| SG10202102885UA (en) | 2016-05-20 | 2021-05-28 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| US20180127481A1 (en) | 2016-11-09 | 2018-05-10 | Uti Limited Partnership | RECOMBINANT pMHC CLASS II MOLECULES |
| WO2019051126A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
| US20200317790A1 (en) * | 2017-10-03 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| CA3084674A1 (en) * | 2017-12-23 | 2019-06-27 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells and methods of use |
| EP4534560A3 (en) | 2018-03-24 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
-
2020
- 2020-12-02 WO PCT/US2020/062801 patent/WO2021113297A1/en not_active Ceased
- 2020-12-02 IL IL293330A patent/IL293330A/en unknown
- 2020-12-02 CN CN202080090908.XA patent/CN114901678A/zh active Pending
- 2020-12-02 CA CA3163549A patent/CA3163549A1/en active Pending
- 2020-12-02 KR KR1020227021577A patent/KR20220110233A/ko active Pending
- 2020-12-02 EP EP20829434.8A patent/EP4069722A1/en active Pending
- 2020-12-02 JP JP2022532773A patent/JP7726881B2/ja active Active
- 2020-12-02 AU AU2020395122A patent/AU2020395122A1/en active Pending
- 2020-12-02 US US17/780,158 patent/US20220409732A1/en active Pending
-
2025
- 2025-08-07 JP JP2025132396A patent/JP2025159063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010250951B2 (en) | Bifunctional polypeptides | |
| JP2024177479A (ja) | 補体依存性細胞溶解のエフェクター機能の調節のための修飾されたヒトＩｇＭ定常領域 | |
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| JP2020186248A5 (enExample) | ||
| US20220098274A1 (en) | Engineered pd-1 variants | |
| US20120121641A1 (en) | Mhc oligomer and method of making the same | |
| JP2018171063A5 (enExample) | ||
| HRP20231382T1 (hr) | Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba | |
| JP2017527272A5 (enExample) | ||
| IL293330A (en) | mhc ii peptide protein structures and uses thereof | |
| JP2019502694A5 (enExample) | ||
| US11090381B2 (en) | Coiled-coil connector | |
| JP2021512159A5 (enExample) | ||
| Kim et al. | Molecular basis of HLA-C recognition by p58 natural killer cell inhibitory receptors | |
| CA3187459A1 (en) | Serum half-life extended pd-l1 inhibitory polypeptides | |
| JP2023520412A5 (enExample) | ||
| JP2023532760A (ja) | 特異的結合分子 | |
| JP2019518713A5 (enExample) | ||
| JP2025514872A5 (enExample) | ||
| US20240336665A1 (en) | Fusion proteins comprising 072 core peptide and use thereof | |
| JP2024546875A5 (enExample) | ||
| JP2025510786A5 (enExample) | ||
| EP3962937A1 (en) | Artificial signalling molecule | |
| JP2023525822A5 (enExample) | ||
| JP2024533487A5 (enExample) |